Investigators should disclose all financial interests:
This article was originally published in Clinica
All financial arrangements between a clinical investigator and a sponsor should be disclosed, believes Public Citizen. Commenting on the US FDA's proposed rule on financial disclosure, Public Citizen's Health Research Group says that while it disagrees with any shareholding threshold before disclosure is triggered, it considers a "trigger" threshold of $10,000 more appropriate than the 5% of total equity put forward by the agency. Elimination of "significant payments of other sorts" offers a substantial loophole, says HRG: any type of economic tie between a sponsor and a clinical investigator is regarded as presenting a potential conflict of interest. If a threshold is set for significant payments, the consumer group opposes any move to raise it above the proposal of $5,000 annually.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.